All In Biotech

Drug Trial Radar · NCT01564784

A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATOR'S CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Last checked: Nov 20, 2026Latest source record: Jan 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

326

Actual

Start

Aug 2, 2012

Primary completion

Mar 8, 2016

Study completion Jan 4, 2017

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
UCB Pharma
First posted
Mar 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the efficacy, in terms of complete responses and overall survival, of inotuzumab ozogamicin versus investigator's choice of chemotherapy.

Conditions

  • Acute Lymphoblastic Leukemia

Interventions

  • inotuzumab ozogamicinDrug

    Dose: inotuzumab ozogamicin 0.8-0.5 mg/m\^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6

  • FLAG (fludarabine, cytarabine and G-CSF)Drug

    Dose: cytarabine 2.0 g/m\^2/day IV days 1-6 fludarabine30 mg/m\^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4

  • HIDAC (high dose cytarabine)Drug

    cytarabine 3 g/m\^2 IV every 12 hours for up to 12 times

  • cytarabine and mitoxantroneDrug

    mitoxantrone 12 mg/m\^2 IV days 1-3 cytarabine 200 mg/m\^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint Adjudication Committee (EAC)Time frame: Screening, Day 16 to 28 of Cycles 1, 2 and 3, then every 1 to 2 cycles (or as clinically indicated) up to approximately 4 weeks (end of treatment [EoT]) from the last dose
  2. Overall Survival (OS)Time frame: Up to 5 years after randomization or 2 years from randomization of the last participant, whichever occurs first.

Locations

198 sites in 20 countries. Site status is shown where the registry gives one.

  • Investigational Drug Services - UC San Diego Moores Cancer Center

    La Jolla, California

  • UC San Diego Medical Center - La Jolla

    La Jolla, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Children's Center for Cancer and Blood Diseases, Childrens Hospital Los Angeles

    Los Angeles, California

  • Keck Hospital of USC

    Los Angeles, California

  • LAC+USC Medical Center

    Los Angeles, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services

    Los Angeles, California

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Drug Information/Investigation Drug

    Los Angeles, California

  • UCLA Hematology/Oncology Clinic

    Los Angeles, California

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California

  • UCLA Rrmc

    Los Angeles, California

  • UC Irvine Medical Center

    Orange, California

  • Children's Hospital of Orange County

    Orange, California

  • UC Irvine Medical Center

    Orange, California

  • Freidenrich Center for Translational Research (CTRU), Stanford University

    Palo Alto, California

  • UC San Diego Medical Center - Hillcrest

    San Diego, California

  • Martha Hamilton, Investigational Drug Services, Dept of Pharmacy

    Stanford, California

  • Stanford Cancer Institute

    Stanford, California

  • Stanford University Hospital and Clinics

    Stanford, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • University of Colorado Hospital, Cancer Center Infusion Center

    Aurora, Colorado

  • University of Colorado Hospital

    Aurora, Colorado

  • Yale-New Haven Hospital & Smilow Cancer Center

    New Haven, Connecticut

  • Miami Children's Hospital

    Miami, Florida

  • MD Anderson Cancer Center Orlando - 5th Floor Investigational Pharmacy

    Orlando, Florida

  • MD Anderson Cancer Center Orlando

    Orlando, Florida

  • Orlando Heart Health Institute

    Orlando, Florida

  • Orlando Regional Medical Center

    Orlando, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Investigational Drug Service, Emory University Clinic

    Atlanta, Georgia

  • The Emory Clinic

    Atlanta, Georgia

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia

  • Blood and Marrow Transplant Group of Georgia

    Atlanta, Georgia

  • Northside Hospital

    Atlanta, Georgia

  • Georgia Regents Medical Center Pharmacy, Georgia Regents University Cancer Center

    Augusta, Georgia

  • Georgia Regents University

    Augusta, Georgia

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois

  • Northwestern Medicine Developmental Therapeutics Institute

    Chicago, Illinois

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.